Advanced or metastatic UTUC in a Lynch syndrome patient can be treated with anti–PD-1/PD-L1 therapy—such as pembrolizumab or nivolumab—analogous to MSI-high colorectal cancer [50,53]. Here, PDCD1 is linked to Lynch syndrome.